Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

#3711

Introduction: Homecare is an established delivery method utilised by the UK NHS. In the UK, patients with GEP-NETs on a stable dose of LAN can be trained for self or partner administration or can be administered by a homecare nurse. Both methods remove LAN related activity in an acute setting, negating costs to the provider. The National Tariff payment system is a set of prices to help the NHS deliver value to patients. The price, as set out in the 2022/23 National Tariff workbook, for a single professional follow-up endocrinology outpatient appointment is £101. The cost of this activity, as set out in the 2020/21 National Schedule of Costs, is £197. This represents a potential unreimbursed cost to the NHS of £96 per outpatient appointment.

Aim(s): Demonstrate the potential reduction in unreimbursed NHS costs associated with acute outpatient activity, by increasing home-based administration of LAN for the treatment of GEP-NETs.

Materials and methods: Using a prevalence rate of 34.9 per 100,000 individuals, there are an estimated 3583 patients with GEP-NETs who are potentially suitable for treatment with somatostatin analogues (SSAs) in the UK. An analysis was completed to evaluate unreimbursed costs incurred over 5 years for patients receiving administration of a SSA, including LAN in an acute setting versus home-based administration.

Conference:

Presenting Author: Bolton R

Authors: Higgs K, Halpin C, Bolton R, Frankcom I,

Keywords: gastroenteropancreatic neuroendocrine tumor, lanreotide autogel, home administration, un-reimbursed costs,